Rising Prevalence Of Pcos Fuels Demand For Iron Deficiency Injectables: An Emerging Driver Transforming The Iron Deficiency Injectable Market Landscape

The Iron Deficiency Injectable Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Projected Growth of the Iron Deficiency Injectable Market?
In the recent years, the market size for injectable iron deficiency treatments has seen substantial growth. The market, which was valued at $14.06 billion in 2024, is projected to escalate to $15.37 billion in 2025, registering a compound annual growth rate (CAGR) of 9.3%. This growth during the historic period can be credited to the widespread treatment of iron deficiency anemia, the rise in bariatric surgery patients, an increase in pediatric and adolescent patients, as well as the increase in pregnancies.

The market for injectable iron deficiency treatments is set to experience accelerated expansion in the coming years. It is projected to reach a value of $23.13 billion by 2029, with a compound annual growth rate (CAGR) of 10.8%. Multiple factors contribute to this growth forecast, such as an aging population, worldwide health campaigns, governmental initiatives, rising treatments for chronic diseases, and swift replenishment of iron. Key future trends cover improvements in iron formulations, utilization of digital health solutions, advancements in therapy for iron deficiency injectables, and increased acceptance of iron-based medications.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12907

What Are the Different Iron Deficiency Injectable Market Segments?
The iron deficiency injectable market covered in this report is segmented -

1) By Type: Iron Dextran, Iron Sucrose, Ferric Carboxymaltose
2) By Branded or Generics: Branded, Generics
3) By Application: Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:
1) By Iron Dextran: Low Molecular Weight Iron Dextran, High Molecular Weight Iron Dextran
2) By Iron Sucrose: Venofer
3) By Ferric Carboxymaltose: Injectafer, Ferinject

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12907&type=smp

What Are the Primary Drivers Shaping the Iron Deficiency Injectable Market?
The surge in polycystic ovary* syndrome (PCOS) cases is anticipated to fuel the expansion of the iron deficiency injectables market in the future. Being a prevalent hormonal condition, PCOS affects individuals with ovaries, especially women in their reproductive years. PCOS tend to cause an overabundance of iron leading to substantial blood loss during periods and resulting in anemia. This condition can be remedied by administering injectable iron deficiency medications. For example, in June 2023, the World Health Organization, an American-specific health institution, reported that globally, PCOS impacts about 8-13% of women of reproductive age, with a whopping 70% remaining undiagnosed. Consequently, the surge of PCOS is spurring the expansion of the iron deficiency injectables market. Continued growth in the iron deficiency injectable market is being driven by the escalating prevalence of malnutrition. Malnutrition represents a medical state marked by a mismatch between the intake of crucial nutrients and the body's dietary requirements. Iron deficiency injectables are given to malnourished individuals to swiftly top up the body's iron reserves and provide a concentrated iron dosage that's rapidly incorporated into the bloodstream. This leads to a rapid rectification of the deficiency. For example, in March 2023, the California Department of Public Health, a governmental agency at the state level in the US, revealed that death cases related to malnutrition rose by 22.36% to 1,406 in 2022 from 1,149 in 2021. Therefore, the increasing prevalence of malnutrition will continue to drive the expansion of the iron deficiency injectable market going forward.

Which Companies Are Leading in the Iron Deficiency Injectable Market?
Major companies operating in the iron deficiency injectable market are Daiichi Sankyo Company Limited, Pfizer Inc., Aetna Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, AstraZeneca PLC, GSK PLC, Fresenius Medical Care, Teva Pharmaceutical Industries Ltd., Mylan N.V., B Braun Medical Inc., Sandoz, Fresenius Kabi AG, Cipla Limited, Emcure Pharmaceuticals Ltd., AMAG Pharmaceuticals Inc., Luitpold Pharmaceuticals Inc., Akebia Therapeutics Inc., Covis Pharma GmbH, Keryx Biopharmaceuticals Inc., Rockwell Medical Inc., American Regent Inc., Galen Medical Group.

What Trends Are Expected to Dominate the Iron Deficiency Injectable Market in the Next 5 Years?
Leading firms in the iron deficiency injectables market, such as the American-based healthcare company, Daiichi Sankyo Company, and American Regent Inc., an injectables manufacturer also based in the US, have been focused on creating new treatments like INJECTAFER to secure their market standing. In June 2023, they introduced INJECTAFER (ferric carboxymaltose injection), an innovative cure for iron deficiency that has been approved by the Food And Drug Administration, a government agency in the US. This treatment, which is the first and only intravenous iron replacement therapy for adults experiencing chronic and escalating heart failure, has received FDA endorsement. During its trial phase, INJECTAFER was assessed in over 40 different clinical trials involving more than 8,800 participants from around the world. The recent FDA approval enhances INJECTAFER's proven and successful utilization in patients, particularly among adults and children with iron-deficient anemia and heart failure.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/iron-deficiency-injectable-global-market-report

What Are the Top Revenue-Generating Geographies in the Iron Deficiency Injectable Market?
North America was the largest region in the iron deficiency injectable market in 2024. The regions covered in iron deficiency injectable market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Iron Deficiency Injectable Market?
2. What is the CAGR expected in the Iron Deficiency Injectable Market?
3. What Are the Key Innovations Transforming the Iron Deficiency Injectable Industry?
4. Which Region Is Leading the Iron Deficiency Injectable Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.